Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes

Diabetologia
S GargDouglas B Muchmore

Abstract

The efficacy and safety of human insulin inhalation powder (HIIP) plus insulin glargine were compared to subcutaneously injected insulin (SC insulin) plus insulin glargine in patients with type 1 diabetes. This was a randomised, open-label crossover study in which one group of patients received preprandial HIIP plus insulin glargine for 12 weeks, followed by the same duration with preprandial SC insulin (lispro or regular) plus insulin glargine. Another group of patients received the reverse treatment sequence. The trial was designed as a non-inferiority comparison of the two treatments for effect on HbA(1c); blood glucose levels were also monitored. Safety assessments included adverse event reporting and hypoglycaemic events. HbA(1c) at endpoint was 7.95+/-0.12% for the HIIP treatment and 8.06+/-0.12% for the SC insulin treatment; mean changes from baseline to endpoint were -0.08 and 0.00%, respectively, (p=NS). The upper limit of the 95% CI of mean difference in HbA(1c) between the two treatments was 0.02%, indicating that HIIP was not inferior relative to SC insulin, as measured against the pre-defined margin of 0.3%. Fasting blood glucose was significantly lower for HIIP treatment (8.09+/-0.33 mmol/l; n=117) than for SC ins...Continue Reading

References

Sep 1, 1995·American Journal of Respiratory and Critical Care Medicine
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Aug 4, 1998·Journal of Applied Physiology·D A EdwardsR Langer
Apr 30, 1999·Diabetes Research and Clinical Practice·H Overmann, L Heinemann
Feb 15, 2001·Annals of Internal Medicine·W T CefaluUNKNOWN Inhaled Insulin Study Group
May 9, 2002·Expert Opinion on Investigational Drugs·William T CefaluSanjit Bindra
Sep 25, 2002·International Journal of Pharmaceutics·Craig DunbarRick Batycky
Nov 27, 2002·Diabetes Technology & Therapeutics·Andreas PfütznerSolomon S Steiner
Jan 22, 2003·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·André X C N ValenteDavid A Edwards
May 27, 2004·International Journal of Clinical Practice·A H Barnett
Jun 24, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·K RaveD Muchmore
Jun 29, 2005·Diabetes Care·Jay S SkylerUNKNOWN Inhaled Insulin Phase III Type 1 Diabetes Study Group
Sep 2, 2005·Diabetes, Obesity & Metabolism·Joseph D Brain

❮ Previous
Next ❯

Citations

Nov 28, 2007·Pharmaceutical Research·Reinhard Vehring
Jun 6, 2007·Current Diabetes Reports·William T Cefalu
Oct 22, 2013·International Journal of Pharmaceutics·Paul ZarogoulidisKonstantinos Zarogoulidis
Jul 10, 2007·Diabetes Technology & Therapeutics·S Edwin FinebergNaomi S Fineberg
Jul 10, 2007·Diabetes Technology & Therapeutics·Matthew HegewaldRobert L Jensen
Jul 10, 2007·Diabetes Technology & Therapeutics·Irl B Hirsch
Jul 10, 2007·Diabetes Technology & Therapeutics·Douglas B MuchmoreJanet Tobian
Sep 30, 2009·Diabetes Technology & Therapeutics·Richard M BergenstalDouglas B Muchmore
Sep 30, 2009·Diabetes Technology & Therapeutics·Amparo de la PeñaDouglas B Muchmore
Jun 22, 2011·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Paul ZarogoulidisEfstratios Maltezos
Dec 23, 2008·The Journal of Pharmacology and Experimental Therapeutics·Dale S EdgertonThomas R Strack
May 6, 2006·BMJ : British Medical Journal·Emma Morton-Eggleston, Eugene J Barrett
Feb 1, 2008·Expert Review of Pharmacoeconomics & Outcomes Research·Bastiaan E de Galan
Sep 14, 2007·Expert Review of Medical Devices·Julio RosenstockJennifer Schmitke
Dec 9, 2014·Expert Opinion on Drug Delivery·Jahidur RashidFakhrul Ahsan
May 14, 2014·Advanced Drug Delivery Reviews·David CipollaAnthony Hickey
Apr 17, 2014·Advanced Drug Delivery Reviews·Anne Marie HealyLidia Tajber
Feb 10, 2007·Current Medical Research and Opinion·Risa P HayesJennifer Schmitke
Feb 9, 2007·Journal of Pharmaceutical Sciences·Negar SadrzadehCynthia L Stevenson
Dec 7, 2007·Best Practice & Research. Clinical Endocrinology & Metabolism·Sabine Arnolds, Tim Heise
Oct 10, 2006·Diabetes, Obesity & Metabolism·Douglas B Muchmore, Jeffrey R Gates
Dec 13, 2006·British Journal of Pharmacology·D SchaafsmaS A Nelemans
Aug 22, 2006·Metabolism: Clinical and Experimental·Marc S Rendell, Lois Jovanovic
Sep 6, 2007·Endocrine Reviews·S Edwin FinebergAlan S Krasner
Apr 19, 2012·Drug Metabolism and Pharmacokinetics·Keisuke OdaMikihisa Takano
Sep 12, 2006·The Journal of Pharmacology and Experimental Therapeutics·Dale S EdgertonAlan D Cherrington
Jan 26, 2021·European Journal of Medicinal Chemistry·Valentina SalaAlessandra Ghigo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.